• Services
    • Infusion Management Services Navigation Header
      • Infusion Management Services
    • Ambulatory Infusion Centers Header
      • Ambulatory Infusion Centers
    • Pharmacy Services Navigation Header
      • Pharmacy Services
    • Wholesale Distribution Navigation Header
      • Wholesale Distribution
    • Clinical Outcomes Research Navigation Header
      • Clinical Outcomes Research
    • Outsourced Patient Support and Hub Services Navigation Header
      • Outsourced Patient Support and Hub Services
  • Company
    • About Us
    • News & Events
    • History of Infusion
  • Careers
  • Contact Us
  • Contact Us
  • Services
    • Infusion Management Services
    • Ambulatory Infusion Centers
    • Pharmacy Services
    • Wholesale Distribution
    • Clinical Outcomes Research
    • Outsourced Patient Support and Hub Services
  • Company
    • About Us
    • News & Events
    • History of Infusion
  • Careers
Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers

Dalbavancin: A Nationwide Outpatient Experience in Physician Office Infusion Centers

Jun 13, 2016 | News

SUGAR LAND, TX (May 23, 2016) – Dalbavancin is a long-acting lipoglycopeptide, approved for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. A retrospective study was conducted of 105 patients treated...
Antimicrobial Regimen and Safety of Pediatric Outpatient Treatment in a POIC

Antimicrobial Regimen and Safety of Pediatric Outpatient Treatment in a POIC

Jan 25, 2016 | News

SUGAR LAND, TX (January 25, 2016) – Pediatric outpatient antimicrobial therapy (OPAT) is increasing, however, data on management, safety, and clinical outcomes are limited. A two-year retrospective, observational study was conducted of 64 pediatric patients receiving...
A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia OPAT in a POIC

A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia OPAT in a POIC

Oct 10, 2015 | News

SAN DIEGO, CA (October 10, 2015) – Septicemia constitutes a major cause for 30-day hospital readmissions and is the most expensive condition treated in U.S. hospitals according to the Agency for Healthcare Research and Quality, Healthcare Cost, and Utilization...
Low Hospital Admission Rates Following POIC-Based Outpatient Treatment with Intravenous Antibiotics

Low Hospital Admission Rates Following POIC-Based Outpatient Treatment with Intravenous Antibiotics

Dec 1, 2014 | News

PHILADELPHIA, PA (October 10, 2014) – Outpatient antimicrobial therapy (OPAT) provided by a physician office infusion center revealed an overall low 30-day hospital admission rate of 6.8% compared to 26% previously reported. This collaborative, retrospective study...
Comparison of Outpatient Antimicrobial Therapy (OPAT) in a POIC vs. Traditional Home Health Care

Comparison of Outpatient Antimicrobial Therapy (OPAT) in a POIC vs. Traditional Home Health Care

Oct 29, 2014 | News

PHILADELPHIA, PA (October 10, 2014) – Outpatient antimicrobial therapy (OPAT) in a physician office infusion center showed improved quality of care in contrast to a traditional home health care setting. A collaborative, retrospective study reviewed patient data from...
Clinical Success in Outpatient Treatment of Complicated Urinary Tract Infections with Ertapenem

Clinical Success in Outpatient Treatment of Complicated Urinary Tract Infections with Ertapenem

Nov 14, 2013 | News

SAN FRANCISCO, CA (October 4, 2013) – A retrospective database review was conducted of patients aged 18 and older receiving ertapenem therapy for UTI between July 1, 2010, and December 31, 2013. Seventy-five patients with a UTI diagnosis and available culture data...
Page 9 of 12« First«...7891011...»Last »

Recent Posts

  • Real-World Experience with Rezafungin: A Novel Long-Acting Echinocandin
  • Immune Globulin Subcutaneous 16.5% in Immunoglobulin-Naïve Patients with Primary Immunodeficiency
  • Effectiveness of A Community-based Inflammatory Bowel Disease Medical Home Compared to Patients not in a Medical Home
  • Real-world Effectiveness and Onset of Action of Vedolizumab as a First-line Biologic in Biologic-Naïve Patients With Ulcerative Colitis
  • Immune Globulin Subcutaneous 16.5% in Treatment of Primary Immunodeficiency: A Two-Year, Multi-Center Analysis

Recent Comments

    Archives

    • April 2025
    • March 2025
    • February 2025
    • December 2024
    • October 2024
    • August 2024
    • May 2024
    • April 2024
    • February 2024
    • November 2023
    • October 2023
    • June 2023
    • February 2023
    • January 2023
    • November 2022
    • October 2022
    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • November 2021
    • October 2021
    • September 2021
    • November 2020
    • October 2020
    • July 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • August 2019
    • July 2019
    • May 2019
    • April 2019
    • February 2019
    • December 2018
    • October 2018
    • July 2018
    • June 2018
    • January 2018
    • December 2017
    • October 2017
    • July 2017
    • June 2017
    • March 2017
    • October 2016
    • June 2016
    • January 2016
    • October 2015
    • December 2014
    • October 2014
    • November 2013
    • October 2013
    • July 2013
    • February 2013
    • January 2013
    • December 2012
    • November 2012
    • October 2012
    • April 2012
    • February 2012
    • January 2012
    • October 2011
    • January 2011
    • October 2010
    • October 2009
    • October 2008

    Categories

    • Blog
    • Clinical Outcomes
    • Cost Savings
    • Events
    • Infusion Management Services
    • New Therapies & Programs
    • News
    • Persistence
    • Services
    • Special Populations

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Follow
    • Follow
    • Follow
    • Contact Us
    • Careers
    • Terms and Conditions
    • Privacy Policy
    • Client Login

    2150 Town Square Place Suite 395, Sugar Land, TX  77479
    (800)-422-2204

    © Healix Infusion Therapy